- Home
- GYRE vs NBN Comparison
GYRE vs NBN Comparison
Compare GYRE & NBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- NBN
- Stock Information
- Founded
- GYRE 2002
- NBN 1872
- Country
- GYRE United States
- NBN United States
- Employees
- GYRE N/A
- NBN N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- NBN Major Banks
- Sector
- GYRE Health Care
- NBN Finance
- Exchange
- GYRE Nasdaq
- NBN Nasdaq
- Market Cap
- GYRE 897.1M
- NBN 811.6M
- IPO Year
- GYRE N/A
- NBN N/A
- Fundamental
- Price
- GYRE $7.28
- NBN $95.69
- Analyst Decision
- GYRE Strong Buy
- NBN Hold
- Analyst Count
- GYRE 1
- NBN 1
- Target Price
- GYRE $18.00
- NBN $115.00
- AVG Volume (30 Days)
- GYRE 92.0K
- NBN 95.3K
- Earning Date
- GYRE 11-12-2025
- NBN 10-28-2025
- Dividend Yield
- GYRE N/A
- NBN 0.04%
- EPS Growth
- GYRE N/A
- NBN 32.98
- EPS
- GYRE 0.02
- NBN 10.08
- Revenue
- GYRE $102,189,000.00
- NBN $204,086,000.00
- Revenue This Year
- GYRE $16.80
- NBN $17.75
- Revenue Next Year
- GYRE $50.29
- NBN $9.91
- P/E Ratio
- GYRE $428.23
- NBN $9.48
- Revenue Growth
- GYRE N/A
- NBN 33.67
- 52 Week Low
- GYRE $6.11
- NBN $75.29
- 52 Week High
- GYRE $19.00
- NBN $113.01
- Technical
- Relative Strength Index (RSI)
- GYRE 44.66
- NBN 35.11
- Support Level
- GYRE $7.20
- NBN $93.45
- Resistance Level
- GYRE $7.72
- NBN $111.22
- Average True Range (ATR)
- GYRE 0.28
- NBN 3.07
- MACD
- GYRE -0.01
- NBN -1.65
- Stochastic Oscillator
- GYRE 28.58
- NBN 10.84
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About NBN Northeast Bank
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.